BioNexus Gene Lab vs Sera Prognostics
BGLC and SERA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGLC and SERA compare
Sera Prognostics is the larger company, worth 29 times as much as BioNexus Gene Lab ($78.1M against $2.7M).
Sera Prognostics grew revenue faster over the last twelve months (1.1% versus −67.3% for BioNexus Gene Lab).
BioNexus Gene Lab keeps more of each dollar of sales as profit, with a net margin of −82.4% compared with −34867% at Sera Prognostics.
BioNexus Gene Lab scores higher on the StockData Score (8 against 5 for Sera Prognostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGLC | SERA |
|---|---|---|
| Size and price | ||
| Market cap | $2.7M | $78.1M |
| Share price | $0.906 | $1.98 |
| Change, 1 year | −82.4% | −26.4% |
| Change, 5 years | −99.6% | −81.7% |
| Beta (5Y) | 0.89 | 1.22 |
| Employees | 6 | – |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 814× |
| P/B | 0.3× (better) | 1.5× |
| FCF yield | −32.1% (better) | −37.1% |
| Fair value | $7.49 | – |
| Margin of safety | 87.9% | – |
| Growth | ||
| Revenue growth (TTM) | −67.3% | 1.1% (better) |
| Revenue growth, 5Y average | −8.2% | 26.5% (better) |
| Profitability | ||
| Gross margin | 12.3% | – |
| Operating margin | −81.8% (better) | −38755% |
| Net margin | −82.4% (better) | −34867% |
| FCF margin | −27.3% (better) | −30199% |
| Return on equity | −33.7% (better) | −49.7% |
| Return on invested capital | −32.3% (better) | −124% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −5315.0× |
| Current ratio | 6.08 (better) | 1.88 |
| Altman Z-score | 0.48 (better) | −5.41 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.49% | 43.2% |
| Held by insiders | 31.0% | 30.4% |
| Insider net buying, 12 months | – | −$524K |
| Short interest, % of float | 0.16% | 0.80% |
Go deeper
- BGLC stock overview
- BGLC income statement
- BGLC valuation and score
- SERA stock overview
- SERA income statement
- SERA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.